Ocugen analyst ratings
Ocugen analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/15/2022 | 323.28% | Roth Capital | → $8 | Reinstates | → Buy |
| 06/02/2022 | 138.1% | Cantor Fitzgerald | → $4.5 | Initiates Coverage On | → Overweight |
| 05/12/2022 | 270.37% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 02/28/2022 | 323.28% | HC Wainwright & Co. | $10 → $8 | Maintains | Buy |
| 06/11/2021 | 217.46% | Roth Capital | $10 → $6 | Downgrades | Buy → Neutral |
| 06/11/2021 | 429.1% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy |
| 05/07/2021 | 482.01% | Cantor Fitzgerald | $15 → $11 | Downgrades | Overweight → Neutral |
| 03/03/2021 | 693.65% | Cantor Fitzgerald | $4 → $15 | Maintains | Overweight |
| 02/09/2021 | 587.83% | Chardan Capital | $0.7 → $13 | Downgrades | Buy → Neutral |
| 02/04/2021 | 138.1% | HC Wainwright & Co. | → $4.5 | Upgrades | Neutral → Buy |
| 11/17/2020 | -47.09% | Roth Capital | → $1 | Initiates Coverage On | → Buy |
| 10/09/2020 | -47.09% | Cantor Fitzgerald | → $1 | Initiates Coverage On | → Overweight |
| 06/03/2020 | -62.96% | Chardan Capital | $2 → $0.7 | Maintains | Buy |
| 06/01/2020 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 12/20/2019 | — | HC Wainwright & Co. | Initiates Coverage On | → Buy | |
| 11/27/2019 | 5.82% | Chardan Capital | → $2 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 06/15/2022 | 323.28% | 羅斯資本 | → $8 | 恢復 | →購買 |
| 06/02/2022 | 138.1% | 康託·菲茨傑拉德 | → $4.5 | 開始承保 | →超重 |
| 05/12/2022 | 270.37% | HC Wainwright公司 | $8 → $7 | 維護 | 買 |
| 02/28/2022 | 323.28% | HC Wainwright公司 | $10 → $8 | 維護 | 買 |
| 06/11/2021 | 217.46% | 羅斯資本 | $10 → $6 | 評級下調 | 購買→中性 |
| 06/11/2021 | 429.1% | HC Wainwright公司 | $12 → $10 | 維護 | 買 |
| 05/07/2021 | 482.01% | 康託·菲茨傑拉德 | $15 → $11 | 評級下調 | 超重→中性 |
| 03/03/2021 | 693.65% | 康託·菲茨傑拉德 | $4 → $15 | 維護 | 超重 |
| 02/09/2021 | 587.83% | 查爾丹資本 | $0.7 → $13 | 評級下調 | 購買→中性 |
| 02/04/2021 | 138.1% | HC Wainwright公司 | → $4.5 | 升級 | 中性→購買 |
| 11/17/2020 | -47.09% | 羅斯資本 | → $1 | 開始承保 | →購買 |
| 10/09/2020 | -47.09% | 康託·菲茨傑拉德 | → $1 | 開始承保 | →超重 |
| 06/03/2020 | -62.96% | 查爾丹資本 | $2 → $0.7 | 維護 | 買 |
| 06/01/2020 | — | HC Wainwright公司 | 評級下調 | 購買→中性 | |
| 12/20/2019 | — | HC Wainwright公司 | 開始承保 | →購買 | |
| 11/27/2019 | 5.82% | 查爾丹資本 | → $2 | 開始承保 | →購買 |
Ocugen Questions & Answers
Ocugen問答
The latest price target for Ocugen (NASDAQ: OCGN) was reported by Roth Capital on June 15, 2022. The analyst firm set a price target for $8.00 expecting OCGN to rise to within 12 months (a possible 323.28% upside). 4 analyst firms have reported ratings in the last year.
羅斯資本於2022年6月15日報道了歐庫根(納斯達克：OCGN)的最新目標價。這家分析公司將目標價定為8美元，預計OCGN將在12個月內上漲至(可能上漲323.28%)。去年有4家分析公司公佈了評級。
The latest analyst rating for Ocugen (NASDAQ: OCGN) was provided by Roth Capital, and Ocugen their buy rating.
羅斯資本提供了對歐庫根(納斯達克：OCGN)的最新分析師評級，歐庫根給予了他們的買入評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ocugen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ocugen was filed on June 15, 2022 so you should expect the next rating to be made available sometime around June 15, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公共財務報表，與歐庫根的高管和客户交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Ocugen的上一次評級是在2022年6月15日提交的，所以你應該預計下一次評級將在2023年6月15日左右的某個時候提供。
While ratings are subjective and will change, the latest Ocugen (OCGN) rating was a with a price target of $0.00 to $8.00. The current price Ocugen (OCGN) is trading at is $1.89, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但Ocugen(OCGN)的最新評級為A，目標價在0.00美元至8.00美元之間。目前Ocugen(OCGN)的交易價格為1.89美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。